Our Vision
To be recognized as the nation's preeminent medical aesthetics corporate group—setting the definitive industry benchmark for ethical business practices, clinician-first partnership models, and superior patient experience standards.
Avyra Medical Group is an elite healthcare operating and investment platform based in the United States. We partner with premier aesthetic practices and clinicians, pairing uncompromised medical excellence with institutional governance, disciplined financial stewardship, and transformative operational infrastructure.
"Enduring leadership in medical aesthetics requires aligning sophisticated capital with genuine clinical autonomy and patient trust."
Headquartered in the United States, Avyra Medical Group was founded to provide leading medical aesthetic practices with the financial sophistication, operational leadership, and strategic scale necessary to flourish in an evolving healthcare landscape.
The medical aesthetics industry has reached an inflection point. While patient demand for non-invasive aesthetic treatments continues to accelerate, individual practice owners face rising administrative burdens, fragmented supply chains, complex regulatory frameworks, and rapidly changing device lifecycles.
Avyra Medical Group resolves this challenge. Rather than imposing rigid corporate mandates, we operate as a collaborative platform. We provide partner practices with institutional capital, automated operational systems, advanced financial modeling, and marketing intelligence—while leaving clinical judgment entirely in the hands of board-certified clinicians.
Our governance model ensures that clinical integrity is never subordinated to short-term commercial pressures. By fostering long-term equity alignment, we build lasting healthcare enterprises characterized by clinical excellence, exceptional employee retention, and sustainable market leadership.
Two governing principles that steer Avyra Medical Group's strategic growth, capital allocation, and physician partnerships across the United States.
To be recognized as the nation's preeminent medical aesthetics corporate group—setting the definitive industry benchmark for ethical business practices, clinician-first partnership models, and superior patient experience standards.
To empower visionary aesthetic clinicians through centralized financial expertise, enterprise-grade operations, and continuous technological modernization, ensuring every affiliated practice achieves sustainable profitability and operational excellence.
Every corporate decision, acquisition, and strategic partnership at Avyra is anchored in four fundamental commitments.
We believe treatment decisions must always be made by qualified practitioners. Our corporate function is strictly to empower and support, never to compromise clinical judgment.
We apply disciplined capital allocation, institutional treasury governance, and transparent fiscal reporting to ensure enduring equity value for all partners.
We continuously evaluate emerging medical technologies, embracing only evidence-informed, regulatory-cleared devices and methodologies that advance patient care.
From patient privacy and HIPAA compliance to staff development and fair vendor relations, integrity remains our foundational operating standard.
Avyra Medical Group’s corporate strategy integrates enterprise management, clinical quality governance, and technological modernization without making unsupported clinical claims.
We remove the administrative friction that prevents aesthetic practices from realizing their full potential. By centralizing core enterprise services, our partner practices achieve significant cost efficiencies while elevating executive decision-making.
Quality in medical aesthetics requires structured oversight, continuous medical education, and strict adherence to federal and state health regulations. Avyra maintains a formal Clinical Advisory Council to uphold industry-leading standards.
Rather than chasing speculative trends, Avyra conducts rigorous technical and commercial vetting of all capital equipment and software before rolling them out across our network.
Our partnership approach is crafted to preserve the distinct reputation and patient relationships each practice has established, while empowering founders with liquidity and long-term equity participation.
“Sustainable enterprise value in aesthetic medicine cannot be built through cost-cutting or clinical compromises; it is forged by empowering premier practitioners with institutional capital, operational transparency, and financial clarity.”
Natalie Brooke Harrison is the Co-Founder of Avyra Medical Group, steering the enterprise's capital architecture, strategic growth, and multi-site operational governance. Her professional journey represents an intentional convergence of institutional corporate finance and specialized healthcare leadership.
Holding an MBA with a concentration in finance, Natalie began her career analyzing complex capital allocation, enterprise valuation, and financial operations. As consumer demand for aesthetic medicine began its historic expansion, she recognized a structural vulnerability within the sector: premier aesthetic clinics were delivering extraordinary clinical artistry, yet practice founders were increasingly overwhelmed by escalating administrative complexity, supply chain fragmentation, and impersonal corporate roll-ups that compromised physician autonomy.
Guided by this market insight, Natalie made the pivotal decision to transition her analytical foundation directly into the healthcare space. Over years of directing corporate management and strategic expansion for multi-site aesthetic enterprises, she refined a business philosophy centered on empowering board-certified practitioners with enterprise-grade financial infrastructure rather than imposing bureaucratic constraints.
Today at Avyra, Natalie's cross-disciplinary mastery—spanning financial modeling, high-value device procurement, and physician equity alignment—serves as the foundational engine enabling affiliated practices to unlock enterprise value while upholding uncompromising patient care standards.
Key executive responsibilities directed by Natalie Brooke Harrison across corporate finance, clinical infrastructure, and practice development nationwide.
Institutional capital allocation, balance-sheet management, practice valuation modeling, and syndicated credit facilities.
High-ROI device lifecycle roadmaps, treatment unit economics, and consumables supply chain optimization.
Multi-site operational infrastructure, executive accountability systems, and centralized corporate oversight.
Multi-year portfolio expansion, capital budgeting, enterprise risk mitigation, and long-term equity growth.
Strategic practice acquisitions, commercial technology partnerships, and physician affiliation due diligence.
Physician equity alignment frameworks, talent acquisition, clinical-administrative harmony, and executive mentorship.
Alongside our founding partners, Avyra’s executive leadership unites board-certified surgical oversight, enterprise operational stewardship, and medical technology vetting—empowering partner practices across the nation.
Clinical Advisory Chair
Enterprise Operations
Innovation & Systems
Avyra Medical Group partners with top-tier aesthetic physicians, medical technology innovators, and institutional capital providers to accelerate collective success across the United States.
Tailored for high-performing aesthetic clinics seeking partial or full equity monetization while retaining clinical leadership and practice culture.
Collaborative integration pathways for medical device manufacturers and biotech firms seeking rapid clinical adoption across our nationwide network.
Institutional partnerships designed for healthcare family offices and private equity syndicates seeking disciplined exposure to high-growth aesthetic medicine.
National partner for next-generation energy-based aesthetic systems and radiofrequency micro-needling platforms.
Growth equity partner providing dedicated debt facilities and balance-sheet capacity for regional practice acquisitions.
Academic collaboration group conducting post-market clinical observational trials and aesthetic safety evaluations.
Formulation partner developing pharmaceutical-grade topical serums, post-procedure recovery matrices, and physician-dispensed skincare.
Enterprise EHR and patient scheduling optimization system unifying multi-location clinical records and compliance tracking.
Independent physician review organization offering third-party quality audits and clinician credentialing verification.
Whether you are a practice founder seeking an affiliation discussion, an institutional investor, or an industry partner, we invite you to start a confidential dialogue.
Prospective practice founders, clinical leaders, and institutional healthcare investors are invited to initiate direct, confidential communications with our executive team through our primary corporate pathways.
For high-performing practice founders exploring equity monetization, operational scale, and physician-led succession.
For institutional private equity syndicates, biotechnology partners, capital equipment providers, and corporate affairs.
Direct confidential access to our executive offices in New York and Beverly Hills during standard business hours.
Strict Confidentiality Notice: All initial dialogues are treated as proprietary corporate correspondence and safeguarded by institutional non-disclosure standards.